Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST® T1)

Diabetic Medicine

Volumn 34, Issue 2, 2017, Pages 167-173

  Hirsch, I B ^a   Franek, E ^b   Mersebach, H ^c   Bardtrum, L ^d   Hermansen, K ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c NOVO NORDISK INC   (United States)

^d NOVO NORDISK A S   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DETEMIR; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN ASPART; INSULIN DEGLUDEC, INSULIN ASPART DRUG COMBINATION; LONG ACTING INSULIN;

ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE RASH; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MEAL; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG COMBINATION; METABOLISM; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG COMBINATIONS; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN DETEMIR; INSULIN, LONG-ACTING; MEALS; TREATMENT OUTCOME;

EID: 84975749523     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13068     Document Type: Article

References (28)

1. Kalra S. Insulin degludec aspart: the first co-formulation of insulin analogues. Diabetes Ther Res Treat Educ Diabetes Relat Disord 2014; 5: 65–72.
2. Weinstock RS, Xing D, Maahs DM, Michels A, Rickels MR, Peters AL et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013; 98: 3411–3419.
3. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010; 33: 240–245.
4. Vijan S, Hayward RA, Ronis DL, Hofer TP. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med 2005; 20: 479–482.
5. Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care 2012; 35: 690–692.
6. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104–2114.
7. Novo Nordisk. Ryzodeg (70% insulin degludec/30% insulin aspart) Sumary of Product Characteristics. 2013.
8. Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H. Distinct prandial and basal glucose-lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus. Diabetes Ther Res Treat Educ Diabetes Relat Disord 2014; 5: 255–265.
9. Franek E, Haluzík M, Canecki Varžić S, Sargin M, Macura S, Zacho J et al. IDegAsp provides superior FPG control and reduced hypoglycaemia vs BIAsp 30 in insulin-naive adults with type 2 diabetes: a randomised phase 3 trial. Diabetologia 2014; 57: S380.
10. Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care 2014; 37: 2084–2090.
11. 1c < 7.0%): a meta-analysis. Diabetologia 2014; 57: S400.
12. Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol 2012; 167: 287–294.
13. Dardano A, Bianchi C, Del Prato S, Miccoli R. Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag 2014; 10: 465–475.
14. Hirsch IB, Bode B, Courreges J-P, Dykiel P, Franek E, Hermansen K et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care 2012; 35: 2174–2181.
15. Kurtzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia 2011; 54: S426.
16. Liebl A, Prusty V, Valensi P, Kawamori R, Christiansen JS, Palmer AJ et al. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings. Drugs 2012; 72: 1495–1520.
17. Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA et al. Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab 2014; 16: 922–930.
18. ®) Basal-Bolus Type 1): 2–year results of a randomized clinical trial. Diabet Med 2013; 30: 1293–1297.
19. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489–1497.
20. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859–864.
21. Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther Res Treat Educ Diabetes Relat Disord 2014; 5: 435–446.
22. Brod M, Wolden M, Christensen T, Bushnell DM. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab 2013; 15: 546–557.
23. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007; 9: 209–217.
24. Jensen MG, Hansen M, Brock B, Rungby J. Differences between long-acting insulins for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010; 11: 2027–2035.
25. Poon K, King AB. Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs. Drug Healthc Patient Saf 2010; 2: 213–223.
26. Szypowska A, Golicki D, Groele L, Pańkowska E. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis. Pol Arch Med Wewnętrznej 2011; 121: 237–246.
27. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011; 34: 669–674.
28. Onishi Y, Ono Y, Rabøl R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab 2013; 15: 826–832.